These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 3975640)

  • 1. An investigation of the functional role of the carboxylic groups of heparin. Affinity for antithrombin III and anti-Xa activity of selectively carboxyl esterified heparin.
    Mardiguian J; Trillou M
    Semin Thromb Hemost; 1985 Jan; 11(1):34-6. PubMed ID: 3975640
    [No Abstract]   [Full Text] [Related]  

  • 2. From heparin to heparin fractions and derivatives.
    Coyne E
    Semin Thromb Hemost; 1985 Jan; 11(1):10-2. PubMed ID: 3883496
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of heparin fractions: some overlooked considerations.
    Fareed J
    Semin Thromb Hemost; 1985 Apr; 11(2):227-36. PubMed ID: 3898374
    [No Abstract]   [Full Text] [Related]  

  • 4. Practical considerations on the measurement of low molecular weight heparin anti-Xa activity.
    Aiach M; Roncato M
    Semin Thromb Hemost; 1985 Apr; 11(2):108-11. PubMed ID: 4035362
    [No Abstract]   [Full Text] [Related]  

  • 5. Heparin, its fractions, fragments and derivatives. Some newer perspectives.
    Fareed J
    Semin Thromb Hemost; 1985 Jan; 11(1):1-9. PubMed ID: 3919446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale behind the development of low molecular weight heparin derivatives.
    Hirsh J; Ofosu F; Buchanan M
    Semin Thromb Hemost; 1985 Jan; 11(1):13-6. PubMed ID: 2579436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new synthetic pentasaccharide with increased anti-factor Xa activity: possible role for anionic clusters in the interaction of heparin and antithrombin III.
    Petitou M; Lormeau JC; Choay J
    Semin Thromb Hemost; 1991; 17 Suppl 2():143-6. PubMed ID: 1948084
    [No Abstract]   [Full Text] [Related]  

  • 8. Covalent complexes between low molecular weight heparin fragments and antithrombin III - inhibition kinetics and turnover parameters.
    Hoylaerts M; Holmer E; de Mol M; Collen D
    Thromb Haemost; 1983 Apr; 49(2):109-15. PubMed ID: 6868006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity.
    Choay J; Petitou M; Lormeau JC; Sinaÿ P; Casu B; Gatti G
    Biochem Biophys Res Commun; 1983 Oct; 116(2):492-9. PubMed ID: 6651824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic studies on chemically synthesized pentasaccharide and tetrasaccharide fragments.
    Choay J
    Semin Thromb Hemost; 1985 Apr; 11(2):81-5. PubMed ID: 4035368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular weight of heparin versus biologic activity. Some additional considerations.
    Losito R; Losito C
    Semin Thromb Hemost; 1985 Jan; 11(1):29-33. PubMed ID: 2579437
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis.
    Thomas DP; Merton RE; Barrowcliffe TW; Thunberg L; Lindahl U
    Thromb Haemost; 1982 Jun; 47(3):244-8. PubMed ID: 7112499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactivity of a hereditary abnormal antithrombin III fraction in the inhibition of thrombin and factor Xa.
    Tran TH; Bondeli C; Marbet GA; Duckert F
    Thromb Haemost; 1980 Oct; 44(2):92-5. PubMed ID: 7455997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Xa activity of human hepatic triglyceride lipase.
    Gray E; Bengtsson-Olivecrona G; Olivecrona T; Barrowcliffe TW
    J Lab Clin Med; 1987 Jun; 109(6):653-9. PubMed ID: 3585139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of a sulfated polysaccharide on antithrombin III.
    Czapek EE; Kwaan HC; Szczecinski M
    J Lab Clin Med; 1980 Jun; 95(6):783-90. PubMed ID: 6155418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical and functional study of antithrombin III in newborn infants.
    McDonald MM; Hathaway WE; Reeve EB; Leonard BD
    Thromb Haemost; 1982 Feb; 47(1):56-8. PubMed ID: 7071806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance for blood anticoagulant activity of a 2-sulfate group on L-iduronic acid residues in heparin.
    Rej R; Jaseja M; Perlin AS
    Thromb Haemost; 1989 Jun; 61(3):540. PubMed ID: 2799767
    [No Abstract]   [Full Text] [Related]  

  • 18. Characterization of a new potent heparin. 2nd communication: Chemical analysis of the carbohydrate content and determination of the biological activity of a new potent heparin preparation in vitro, using protamine neutralization and amidolytic methods for factor Xa and thrombin.
    Bhargava AS; Heinick J; Günzel P
    Arzneimittelforschung; 1980; 30(7):1071-4. PubMed ID: 7191289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombin III Geneva: a hereditary abnormal AT III with defective heparin cofactor activity.
    de Moerloose PA; Reber G; Vernet P; Minazio P; Bouvier CA
    Thromb Haemost; 1987 Apr; 57(2):154-7. PubMed ID: 3603409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformational conversion of antithrombin to a fully activated substrate of factor Xa without need for heparin.
    Huntington JA; Gettins PG
    Biochemistry; 1998 Mar; 37(10):3272-7. PubMed ID: 9521646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.